Role of IL‐6‐mediated expression of NS5ATP9 in autophagy of liver cancer cells

2018 ◽  
Vol 233 (12) ◽  
pp. 9312-9319 ◽  
Author(s):  
Hongping Lu ◽  
Ming Han ◽  
Xiaoxue Yuan ◽  
Kelbinur Tursun ◽  
Yu Zhang ◽  
...  
2021 ◽  
Vol 165 ◽  
pp. 54
Author(s):  
Patricia de la Cruz-Ojeda ◽  
M. Ángeles Rodríguez-Hernández ◽  
Elena Navarro-Villarán ◽  
Paloma Gallego ◽  
Pavla Staňková ◽  
...  

2010 ◽  
Vol 24 (S1) ◽  
Author(s):  
Lee Yun‐Kyoung ◽  
Song Yi Park ◽  
Won Sup Lee ◽  
Young‐Joon Surh ◽  
Young‐Min Kim ◽  
...  

Cells ◽  
2020 ◽  
Vol 9 (9) ◽  
pp. 1988
Author(s):  
Leslimar Rios-Colon ◽  
Elena Arthur ◽  
Suryakant Niture ◽  
Qi Qi ◽  
John T. Moore ◽  
...  

Exosomes are membrane-bound extracellular vesicles (EVs) that transport bioactive materials between cells and organs. The cargo delivered by exosomes can alter a wide range of cellular responses in recipient cells and play an important pathophysiological role in human cancers. In hepatocellular carcinoma (HCC), for example, adipocyte- and tumor-secreted factors contained in exosomes contribute to the creation of a chronic inflammatory state, which contributes to disease progression. The exosome-mediated crosstalk between adipocytes and liver cancer cells is a key aspect of a dynamic tumor microenvironment. In this review, we summarize the role of increased adiposity and the role of adipocyte-derived exosomes (AdExos) and HCC-derived exosomes (HCCExos) in the modulation of HCC progression. We also discuss recent advances regarding how malignant cells interact with the surrounding adipose tissue and employ exosomes to promote a more aggressive phenotype.


2020 ◽  
pp. 1-13
Author(s):  
Mutay Aslan ◽  
Ebru Afşar ◽  
Esma Kırımlıoglu ◽  
Tuğçe Çeker ◽  
Çağatay Yılmaz

2017 ◽  
Vol 37 (5) ◽  
pp. 3001-3009 ◽  
Author(s):  
Huina Jia ◽  
Juan Ye ◽  
Jing You ◽  
Xiaoyan Shi ◽  
Wenyi Kang ◽  
...  

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Susu Guo ◽  
Yuxin Chen ◽  
Xiangfei Xue ◽  
Yueyue Yang ◽  
Yikun Wang ◽  
...  

AbstractTribbles homolog 2 (TRIB2) is known to boost liver tumorigenesis via regulating Ubiquitin (Ub) proteasome system (UPS). At least two ways are involved, i.e., acts as an adaptor protein to modulate ubiquitination functions of certain ubiquitin E3 ligases (E3s) and reduces global Ub levels via increasing the proteolysis activity of proteasome. Recently, we have identified the role of TRIB2 to relieve oxidative damage via reducing the availability of Ub that is essential for the ubiquitination and subsequent degradation of Glutathione peroxidase 4 (GPX4). Although GPX4 is a critical antioxidant factor to protect against ferroptosis, the exact evidence showing that TRIB2 desensitizes ferroptosis is lacking. Also, whether such function is via E3 remains unclear. Here, we demonstrated that deletion of TRIB2 sensitized ferroptosis via lifting labile iron in liver cancer cells. By contrast, overexpression of TRIB2 led to the opposite outcome. We further demonstrated that transferrin receptor (TFRC) was required for TRIB2 to desensitize the cells to ferroptosis. Without TFRC, the labile iron pool could not be reduced by overexpressing TRIB2. We also found that beta-transducin repeat containing E3 ubiqutin protein ligase (βTrCP) was a genuine E3 for the ubiquitination of TFRC, and TRIB2 was unable to decline labile iron level once upon βTrCP was knocked out. In addition, we confirmed that the opposite effects on ferroptosis and ferroptosis-associated lipid reactive oxygen species (ROS) generation resulted from knockout and overexpression of TRIB2 were all indispensible of TFRC and βTrCP. Finally, we demonstrated that TRIB2 exclusively manipulated RSL3- and erastin-induced-ferroptosis independent of GPX4 and glutathione (GSH). In conclusion, we elucidated a novel role of TRIB2 to desensitize ferroptosis via E3 βTrCP, by which facilitates TFRC ubiquitiation and finally decreases labile iron in liver cancer cells.


Sign in / Sign up

Export Citation Format

Share Document